TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01665170
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 1 ablet per day for 3 days
Study: NCT00631696
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00002854
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02607930
Drug: ABC/DTG/3TC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600/50/300 milligrams (mg) tablets administered orally, once daily
Study: NCT02607930
Drug: B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50/200/25 mg tablets administered orally, once daily, without regard to food
Study: NCT02607930
Drug: ABC/DTG/3TC Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally, once daily
Study: NCT02607930
Drug: B/F/TAF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally, once daily
Study: NCT01601132
Drug: theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300mg (80mg/15ml elixir)
Study: NCT00630370
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 Placebo tablets, TID, orally, 58 days
Study: NCT00533403
Drug: MK0686
DrugBank: MK-0686 (DB12563)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01021436
Drug: Amikacin inhalation solution (BAY41-6551)
Normalized name: amikacin Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of 800 mg of aerosolized amikacin delivered in two divided doses of 400 mg per aerosol treatment 12 hour
Study: NCT03720353
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 10 days. Capsules will mimic active treatments.
Study: NCT03532009
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral use for approximately 3 months
Study: NCT00524459
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002561
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg/m2
Study: NCT00029679
Drug: Gingko biloba
Normalized name: Gingko Biloba
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04607421
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injection 50 mg/vial, 100 mg/vial, 200 mg/vial, or 350 mg/vial
Study: NCT04607421
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150 mg or 500 mg Tablet
Study: NCT04169893
Drug: Placebo (fasting)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo once in fasting condition
Study: NCT04169893
Drug: Placebo (feeding)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo once after meal condition
Study: NCT02405676
Drug: Prednisone,Vincristine, Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 45mg/m2, D1\~7; Vincristine 1.5mg/m2(MAX 2mg), D1; Cyclophosphamide 300mg/m2, D1; Intrathecal injection, D1;
Study: NCT02405676
Drug: Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;
Study: NCT00585351
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg single dose injection of normal saline (placebo)
Study: NCT02405676
Drug: Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosphamide 1.2g/m2, D1\~5; Etoposide, 60mg/m2, D3\~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1;
Study: NCT00450996
Drug: Topical Steroids
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03291457
Drug: Glucocorticoid Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Because of the observational nature of the study, the choice of glucocorticoid agent, as well as dosing and treatment duration, is at the discretion of the physician in accordance with local clinical practice and local labeling.
Study: NCT01695070
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4mg prolonged release melatonin oral tablets twice daily
Study: NCT02405676
Drug: Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vindelsine 3mg/m2 (MAX 5mg), D1; Cytarabine 2g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;
Study: NCT01699490
Drug: Fluoxetine + Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The curative effect of fluoxetine add-on placebo therapy in the treatment of major depressive disorder.
Study: NCT00947427
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous injections
Study: NCT04430738
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 (mFOLFOX7) or 400 (mFOLFOX6) mg/m\^2 given IV every 2 weeks. Part of FOLFOX regimen.
Study: NCT04430738
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m\^2 (IV bolus after leucovorin) and/or 2400 mg/m\^2 (continuous infusion over 46 hours). Part of FOLFOX regimen.
Study: NCT04430738
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m\^2 is taken twice per day orally on Days 1-14 of each 3 week cycle. Part of CAPOX regimen.
Study: NCT03796858
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo as SC injection.
Study: NCT01548872
Drug: HTK solution
Normalized name: Custodial HTK Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml/kg bolus in 2 minutes
Study: NCT00349063
Drug: Soft contact lens multipurpose disinfection regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01569828
Drug: LCZ696A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01569828
Drug: LCZ696A
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily administration of 400 mg LCZ696 for 5 days
Study: NCT02629874
Drug: Endotoxin
Normalized name: Endotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously
Study: NCT02629874
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02587442
Drug: RadProtect®
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study will evaluate RadProtect® at sequential, escalating dose levels. Once administration is given, study subjects will be followed during 24 hours of hospitalization according to the final injection timing. All subjects will need to return to the hospital for monitoring at 7+2 days after dosing, and follow-up visits by telephone at Day 3, Day 14+2, and Day 28+2 days will need to be conducted.
Study: NCT02641639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline for infusion
Study: NCT00334490
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo in 5 mls distilled water
Study: NCT02255513
Drug: HLD200
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02255513
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02736695
Drug: F-18 AV 1451
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tau binding agent
Study: NCT03735121
Drug: rHuPH20
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuPH20 will be administered as per the scheduled specified in the cohort for Part 1.
Study: NCT01494688
Drug: RO5509554
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO5509554 will be administered Q2W, Q3W or initial biweekly followed by monthly maintenance as intravenous (IV) infusion until disease progression, unacceptable toxicity, death or participant refusal, whichever occurs first.
Study: NCT00412542
Drug: CPT-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg/m\^2 by vein weekly over 90 minutes for 4 weeks, followed by 2 weeks rest
Study: NCT02654314
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg Melatonin nightly, beginning within 24 hours of admission
Study: NCT02034331
Drug: Placebo Iontophoresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: For placebo iontophoresis, the cathode electrode will contain 0.2 ml of preservative-free normal saline; the anode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
Study: NCT02472873
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01562795
Drug: nonsteroid anti-inflammatory drops
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: nonsteroid anti-inflammatory drops plus artificial tear substitute
Study: NCT01562795
Drug: corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: corticosteroids plus artificial tear substitute
Study: NCT01199432
Drug: 5-FU（intravenous infusion）+epirubicin+cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU 200mg/m2 per day from day 1 to day 28 （Continuous intravenous infusion）; epirubicin 65mg/m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed
Study: NCT01712490
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin: 25 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
Study: NCT01199432
Drug: 5-FU（intravenous bolus）+epirubicin+cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU 500mg/m2 per day on day 1 and day 8（intravenous bolus）; epirubicin 65mg /m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed.
Study: NCT01199432
Drug: epirubicin+cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: epirubicin 65mg/m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed.
Study: NCT00929357
Drug: DMARDs or Biologics
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03475732
Drug: XueBiJing injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mL XueBiJing injection (dissolved with 100 mL of 0.9% normal saline),intravenous infusion for 1.25 h, q12h for 5 days
Study: NCT00793845
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: First HDCT
Study: NCT01999309
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The lipid-lowering drug simvastatin is added to normal antipsychotic treatment. One 40 mg simvastatin tablet daily for the treatment period of one year.
Study: NCT01999309
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is added to normal antipsychotic treatment. One identical looking placebo tablet daily for the treatment period of one year.
Study: NCT04065893
Drug: Intensified medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage increase / new onset of Betablocker / medical antiarrhythmic medication according to guideline and clinical practice
Study: NCT00929708
Drug: AZD3199
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder for inhalation, o.d., 4 weeks
Study: NCT00929708
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder for inhalation, b.i.d., 4 weeks
Study: NCT02975271
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT03342898
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline (0.9% NaCl) SC injection.
Study: NCT01717898
Drug: BEZ235
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEZ235 - 200 mg, 300 mg, or 400 mg; po, BID. BEZ235 will be supplied in 200 mg, 300 mg, and 400 mg sachets packaged in boxes.
Study: NCT00040872
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00040872
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02550262
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.0625% Bupivacaine plus fentanyl 2mcg/ml
Study: NCT00258622
Drug: NS1209
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01146990
Drug: ASQ-3, Bayley III, Neurologic exam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Developmental Scales of infant development - Children born to mothers who participated in the 17P-ES-003 study will be enrolled in this study and evaluated using the ASQ-3. Those meeting protocol criteria based on ASQ-3, will be evaluated using the Bayley III and have a neurologic examination.
Study: NCT04223765
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m\^2/day IV for 3 consecutive days
Study: NCT02790177
Drug: NORMAL SALINE
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02325986
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
Study: NCT00640978
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg orally weekly for 4 weeks
Study: NCT03778047
Drug: HC1119
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03493126
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17β-estradiol vaginal cream
Study: NCT02006706
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 - 25 mg/week
Study: NCT00604409
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01788046
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously (IV) three times per week.
Study: NCT02816853
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered.
Study: NCT01924871
Drug: Desflurane with remifentanil
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During the emergence from anesthesia,extubation was performed under 1.0 MAC desflurane with 1.0ng/ml remifentanil
Study: NCT04110028
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04701697
Drug: Recombinant Human Albumin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Recombinant Human Albumin Injection of intravenous infusion
Study: NCT04701697
Drug: HumanAlbumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive HumanAlbumin of intravenous infusion
Study: NCT00570765
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets were administered orally once daily.
Study: NCT04234607
Drug: TQB2450
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study: NCT02254148
Drug: caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose of caffeine given as tablets (day 1 of visits 2 and 3)
Study: NCT04234607
Drug: TQB2450（blank）
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects administrated TQB2450 (blank) intravenously (IV) on Day 1 of each 21-day
Study: NCT04234607
Drug: Anlotinib（blank)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects administrated anlotinib (blank) in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
Study: NCT03841773
Drug: Placebo SL Tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take 2 tablets of randomly assigned study drug sublingually starting on Day 1 for 12 weeks
Study: NCT04515849
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously
Study: NCT01508026
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose matched placebo, oral administration
Study: NCT01722812
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily topical treatment for 14 days
Study: NCT01919671
Drug: Tongxinluo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: for 90 days
Study: NCT01919671
Drug: placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: for 90 days
Study: NCT00879099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatine capsule once a day during two treatment periods. One treatment period lasts for 3 days.
Study: NCT01374828
Drug: Ketolorac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg in 10 ml saline will be injected at the incision sites at the conclusion of the procedure.
Study: NCT02176967
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02176967
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00729859
Drug: Acyline + Testosterone gel
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + placebo oral pill 1 mg daily for 28 days
Study: NCT00729859
Drug: Acyline + testosterone gel + anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + oral anastrozole pill 1 mg daily for 28 days
Study: NCT01757327
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02052609
Drug: KHK4827 140mg SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental1:KHK4827 140mg subcutaneous injection
Study: NCT02052609
Drug: KHK4827 210mg SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental2:KHK4827 210mg subcutaneous injection
Study: NCT02211625
Drug: TRV734 blinded
Approvals — FDA: no, EMA: no, PMDA: no
Description: blinded, multiple ascending dose
Study: NCT02211625
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV734-matched and oxycodone placebo
Study: NCT00871325
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive daily dose of TU-100 placebo. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
Study: NCT03151343
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill, visually identical to active comparator
Study: NCT03109730
Drug: ABI-H0731
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: A novel HBV core protein allosteric modifier (CpAM) which is being developed as a potential therapeutic advance for CHB patients
Study: NCT03109730
Drug: Placebo for ABI-H0731
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic the ABI-H0731 tablet
Study: NCT00850070
Drug: sapropterin
Normalized name: Sapropterin
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive sapropterin 20 mg per kilogram per day for 16 weeks
Study: NCT00850070
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a placebo identical in form and dosage to the active drug daily for 16 weeks.
Study: NCT01724931
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01181908
Drug: single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single dose of GSK1144814 or placebo.
Study: NCT02835742
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04370873
Drug: MK-5475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-5475 32 µg, 100 µg, 195 µg, 360 µg or 380 µg administered as dry powder inhalation according to randomization. Following review of pharmacokinetic (PK) and safety data, a second 7 days of dosing may be initiated. A dose of up to 360 μg up to twice a day may be administered based on PK data. Dosage may be adjusted downwards in Part 2, if indicated by PK results in Part 1.
Study: NCT04370873
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as dry powder inhalation according to randomization
Study: NCT00579098
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet taken by mouth once daily for 90 days
Study: NCT03023462
Drug: Oksykodonhydroklorid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oksykodonhydroklorid, 5 - 10 mg intravenously or orally postoperatively to reduce pain. Repetition until effect.
Study: NCT01868997
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no